91��ɫ

About 91��ɫ Therapeutics

‍

91��ɫ Therapeutics is a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases.

‍

The company’s first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.

‍

91��ɫ’s oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. The company’s autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.

‍

91��ɫ is headquartered in Oxford, UK.

‍

More information: 91��ɫbsite |

‍

Media enquiries

Patrick White, Head of Communications

+44 (0)1235 644 970

patrick.white@gwt.bio

‍